We are pleased to share Wellnex Life (ASX: WNX), owner and developer of some of Australia's leading health brands, has recently released a key ASX announcement.
Wellnex Life Limited (ASX: WNX) (“Wellnex” or “the Company”) is pleased to announce the approval of a new Market Authorisation (MA) for a liquid paracetamol plus caffeine soft gel after the successful submission with TGA of the pharmaceutical dossier.
Announcement Highlights
- Market Authorisation (MA) received for Liquid Paracetamol plus Caffeine Soft Gel
- Builds on the Company’s three other MAs
- Liquid Paracetamol
- Liquid Paracetamol plus Ibuprofen
- Liquid Mini-Ibuprofen - Validation of Company’s innovation to achieve 4 MAs with the Therapeutic Goods of Australia (TGA)
- Further revenue opportunities with new MA, with existing MA’s being used by the Company and domestic and global companies
Wellnex Life's Managing Director Zack Bozinovski said:
"The approval of liquid paracetamol plus caffeine soft gel market authorisation is a great testament to the Company and its internal capabilities. This unique product will provide opportunities not only to use in the Company’s own brands but also opportunities to license it to third parties."
Congratulations to George Karafotias, Zack Bozinovski, the board and the team at Wellnex Life for reaching this significant milestone.
Read the full Wellnex Life ASX announcement here.
To learn more about Wellnex Life and stay up to date with investor information, subscribe to the Company's Chairman’s List.
